Sonnet BioTherapeutics (SONN) Competitors $1.17 -0.01 (-0.84%) Closing price 06/11/2025 03:59 PM EasternExtended Trading$1.17 0.00 (-0.01%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SONN vs. MEIP, ALVR, FLGC, GELS, VYNE, AIMD, EDSA, SYBX, ERNA, and BLRXShould you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include MEI Pharma (MEIP), AlloVir (ALVR), Flora Growth (FLGC), Gelteq (GELS), VYNE Therapeutics (VYNE), Ainos (AIMD), Edesa Biotech (EDSA), Synlogic (SYBX), Eterna Therapeutics (ERNA), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical products" industry. Sonnet BioTherapeutics vs. Its Competitors MEI Pharma AlloVir Flora Growth Gelteq VYNE Therapeutics Ainos Edesa Biotech Synlogic Eterna Therapeutics BioLineRx MEI Pharma (NASDAQ:MEIP) and Sonnet BioTherapeutics (NASDAQ:SONN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation. Does the media favor MEIP or SONN? In the previous week, MEI Pharma and MEI Pharma both had 3 articles in the media. Sonnet BioTherapeutics' average media sentiment score of 0.96 beat MEI Pharma's score of 0.43 indicating that Sonnet BioTherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MEI Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sonnet BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, MEIP or SONN? MEI Pharma has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. Comparatively, Sonnet BioTherapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Do insiders and institutionals hold more shares of MEIP or SONN? 52.4% of MEI Pharma shares are held by institutional investors. Comparatively, 9.4% of Sonnet BioTherapeutics shares are held by institutional investors. 3.1% of MEI Pharma shares are held by company insiders. Comparatively, 2.0% of Sonnet BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, MEIP or SONN? MEI Pharma has higher revenue and earnings than Sonnet BioTherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMEI Pharma$65.30M0.24$17.78M-$4.75-0.49Sonnet BioTherapeutics$1M3.70-$7.44MN/AN/A Do analysts rate MEIP or SONN? Sonnet BioTherapeutics has a consensus price target of $20.00, suggesting a potential upside of 1,609.26%. Given Sonnet BioTherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sonnet BioTherapeutics is more favorable than MEI Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MEI Pharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Sonnet BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer MEIP or SONN? MEI Pharma received 401 more outperform votes than Sonnet BioTherapeutics when rated by MarketBeat users. However, 84.62% of users gave Sonnet BioTherapeutics an outperform vote while only 63.32% of users gave MEI Pharma an outperform vote. CompanyUnderperformOutperformMEI PharmaOutperform Votes42363.32% Underperform Votes24536.68% Sonnet BioTherapeuticsOutperform Votes2284.62% Underperform Votes415.38% Is MEIP or SONN more profitable? MEI Pharma's return on equity of -84.92% beat Sonnet BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MEI PharmaN/A -84.92% -67.53% Sonnet BioTherapeutics N/A -408.93%-174.13% SummaryMEI Pharma and Sonnet BioTherapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SONN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SONN vs. The Competition Export to ExcelMetricSonnet BioTherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.71M$6.85B$5.57B$8.63BDividend YieldN/A2.56%5.28%4.18%P/E RatioN/A8.7827.1220.06Price / Sales3.70255.64412.30157.10Price / CashN/A65.8538.2534.64Price / Book0.896.557.064.70Net Income-$7.44M$143.93M$3.23B$247.88M7 Day Performance1.31%3.84%2.86%2.63%1 Month Performance-12.02%11.20%9.07%6.36%1 Year Performance-34.63%4.18%31.45%14.05% Sonnet BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SONNSonnet BioTherapeutics2.8151 of 5 stars$1.17-0.8%$20.00+1,609.3%-37.4%$3.71M$1M0.0010News CoverageShort Interest ↓MEIPMEI Pharma1.7105 of 5 stars$2.22-0.9%N/A-17.1%$14.79M$65.30M-0.39100News CoverageShort Interest ↑ALVRAlloVirN/A$2.90-2.0%N/A-83.2%$14.63MN/A-0.14110FLGCFlora Growth2.722 of 5 stars$0.64-4.5%$4.00+525.0%-29.8%$14.44M$53.26M-0.65280News CoveragePositive NewsGELSGelteqN/A$1.50-6.3%N/AN/A$14.16MN/A0.00N/ANews CoverageGap DownVYNEVYNE Therapeutics2.5226 of 5 stars$0.93-2.3%$6.25+573.5%-59.7%$14.12M$605K-1.0830Short Interest ↑High Trading VolumeAIMDAinos1.4127 of 5 stars$0.63-6.5%N/A-35.3%$14.02M$106.21K-0.4940Positive NewsEDSAEdesa Biotech3.369 of 5 stars$1.99+1.5%$21.00+955.3%-58.2%$13.98MN/A-1.0620Positive NewsShort Interest ↓SYBXSynlogic1.3358 of 5 stars$1.19+3.7%N/A-24.7%$13.94M$8K-0.2980Short Interest ↑ERNAEterna Therapeutics1.1446 of 5 stars$0.22+0.5%N/A-91.8%$13.66M$535K-0.0310Stock SplitShort Interest ↓Gap UpBLRXBioLineRx3.4837 of 5 stars$4.10-21.9%$26.00+534.1%-80.0%$13.65M$22.34M-0.4740Gap DownHigh Trading Volume Related Companies and Tools Related Companies MEI Pharma Competitors AlloVir Competitors Flora Growth Competitors Gelteq Competitors VYNE Therapeutics Competitors Ainos Competitors Edesa Biotech Competitors Synlogic Competitors Eterna Therapeutics Competitors BioLineRx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SONN) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SONN Stock Free SONN Stock Alerts